Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 2, 2026, CureVac N.V. (CVAC) has a Wall Street consensus price target of $21.00, based on estimates from 8 covering analysts. With the stock currently trading at $4.66, this represents a potential upside of +350.6%. The company has a market capitalization of $1.05B.
Analyst price targets range from a low of $5.00 to a high of $37.00, representing a 152% spread in expectations. The median target of $21.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Hold, with 2 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 1 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, CVAC trades at a trailing P/E of 6.5x. Analysts expect EPS to grow -148.6% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $3.72, with bear and bull scenarios of $-38.33 and $10.11 respectively. Model confidence stands at 18/100, suggesting limited visibility into future performance.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CVAC stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for CVAC is $21, representing 350.6% upside from the current price of $4.66. With 8 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CVAC has a consensus rating of "Hold" based on 8 Wall Street analysts. The rating breakdown is mixed, with 5 Hold ratings making up the largest segment. The consensus 12-month price target of $21 implies 350.6% upside from current levels.
CVAC's current price is $4.66 with a consensus target of $21 (350.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $37 for CVAC, while the most conservative target is $5. The consensus of $21 represents the median expectation. Our quantitative valuation model projects a bull case target of $10 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
CVAC is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 5 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CVAC stock forecast based on 8 Wall Street analysts shows a consensus price target of $21, with estimates ranging from $5 (bear case) to $37 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $4, with bear/bull scenarios of $-38/$10.
Our quantitative valuation model calculates CVAC's fair value at $4 (base case), with a bear case of $-38 and bull case of $10. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 18/100.
Wall Street analysts are very optimistic on CVAC, with a "Hold" consensus rating and $21 price target (350.6% upside). 2 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CVAC analyst price targets range from $5 to $37, a 152% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $21 consensus represents the middle ground. Our model's $-38-$10 range provides an independent fundamental perspective.